Aclarion, Inc. (ACON)
$
6.95
+0.37 (5.32%)
Key metrics
Financial statements
Free cash flow per share
-11.2700
Market cap
4 Million
Price to sales ratio
64.1830
Debt to equity
0
Current ratio
23.8133
Income quality
0.9086
Average inventory
0
ROE
-0.8363
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aclarion, Inc., a healthcare technology company, specializes in developing software applications for magnetic resonance spectroscopy (MRS) across the United States. The company offers the NOCISCAN-LS Post-Processor suite, which includes NOCICALC-LS, designed to receive and process acquired disc MRS data to calculate levels of degenerative pain biomarkers, as well as NOCIGRAM-LS, a clinical decision support software. Founded in 2008 and based in San Mateo, California, Aclarion, which was previously known as Nocimed, Inc. before rebranding in December 2021, has its earnings per share (EPS) reported at -$7,480.22 indicating the company's profitability on a per-share basis. The total costs and expenses for the company amount to $5,558,770.00 reflecting its overall spending. Furthermore, the cost of revenue is $129,767.00 showcasing its production and operational expenses. The EBITDA is -$6,264,322.00 a key indicator of the company's operational profitability; however, the company reported a net loss of -$6,992,927.00 indicating challenges within its operations. The stock is affordable at $9.40 making it suitable for budget-conscious investors. With an average trading volume of 144,246.00 the stock indicates moderate liquidity in the market. Aclarion, Inc. has a market capitalization of $4,040,254.00 categorizing it as a small-cap player in the financial arena. As a significant participant in the Medical - Healthcare Information Services industry, the company contributes immensely to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Aclarion, Inc. (ACON) a good investment?
Investing in Aclarion, Inc. (ACON) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Aclarion, Inc. (ACON)'s stock forecast?
Analysts predict Aclarion, Inc. stock to fluctuate between $5.55 (low) and $3,500.42 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aclarion, Inc.'s market capitalization?
As of 2025-12-05, Aclarion, Inc.'s market cap is $4,040,254, based on 581,750 outstanding shares.
How does Aclarion, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aclarion, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aclarion, Inc. (ACON) stock?
To buy Aclarion, Inc. (ACON) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACON. Place an order (Market, Limit, etc.).
What is the best time to invest in Aclarion, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Aclarion, Inc. stock ever split?
Aclarion, Inc.'s last stock split was 1:27 on 2025-03-28.
How did Aclarion, Inc. perform in the last earnings report?
Revenue: $45,724 | EPS: -$7,480.22 | Growth: -90.62%.
Where can I find Aclarion, Inc.'s investor relations reports?
Visit https://www.aclarion.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aclarion, Inc.?
You can explore historical data from here
What is the all-time high and low for Aclarion, Inc. stock?
All-time high: $21,708 (2022-04-27) | All-time low: $0.61 (2025-03-14).
What are the key trends affecting Aclarion, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced the appointment of Dan Isherwood as UK Commercial Director.
globenewswire.com
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion's breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc.
prismmediawire.com
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted), providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U.
globenewswire.com
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues Webcast scheduled for October 20 th at 12:00 pm PT at the LD Micro Main Event BROOMFIELD, Colo.
globenewswire.com
Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes BROOMFIELD, Colo.
newsfilecorp.com
Presentation on Monday, October 20, 2025 at 12:00 PM PT Broomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the 19th Annual Main Event on Monday, October 20, 2025 at 12:00 PM PT at the Hotel del Coronado in San Diego, CA. Jeff Thramann, Executive Chairman and Brent Ness, Chief Executive Officer will be giving the presentation.
globenewswire.com
BROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its selection as a finalist in the Rising Star - Clinical Diagnostic Device category for the prestigious 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH.
prismmediawire.com
BROOMFIELD, Colo., October 1, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
globenewswire.com
BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe '25 which is now available to investors and stakeholders.
prismmediawire.com
HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
See all news
